Publication: The Medicine Maker
Abstract
The article, The Biosimulation Generation, explores the transformative potential of biosimulation in pharmaceutical R&D as the FDA moves to phase out mandatory animal testing. Highlighting insights from Patrick Smith, Senior Vice President of Translational Sciences at Certara, the piece unpacks how AI-driven biosimulation combines biological, pharmacokinetic, and molecular data to enable model-informed drug development, improve precision, and accelerate progress. It delves into the challenges of regulatory acceptance, the integration of in silico data, and the potential to replace animal testing. Additionally, it details specific use cases, including pediatric epilepsy dosing, and discusses the increasing flexibility and role of biosimulation across drug development stages.
Author: Patrick Smith
Year: July 1, 2025
Learn more about Certara’s Modeling and Simulation Services.
There are numerous instances where clinical data may be unavailable or sparse. However, this should not hinder the progress of your project. Certara’s modeling and simulation services provide valuable insights, de-risk your projects, optimize decisions, and accelerate timelines across all phases of drug development. Our technology-backed services leverage our proprietary platforms for model-informed drug development (MIDD) and are trusted by regulatory authorities worldwide.
